SMA is also pushing ahead with capacity expansion in Germany, where it plans to reach 40 GW. It said it wants to produce solutions for large PV projects and storage systems from 2025 at its ...

German teachers in the US shape the image of Germany in the US and facilitate the transatlantic dialogue between the US and Germany. Unfortunately, the number of German programs at all levels is ...

Novartis is set to launch its one-off gene therapy Zolgensma for the ultra-rare muscle-wasting disease spinal muscular atrophy (SMA) in Germany at the start of July priced at 1,945,000 eu ...

Positive results from its Phase III STEER study mean Novartis could boost sales of its OAV101 IT drug for spinal muscular ...